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ABSTRACT
Objectives: Growth disorders are frequent in diabetic pregnancies. However, they are difficult to predict and capture early 
during pregnancy. These newborns are at risk of obesity, diabetes, and cardiovascular disease. While developing, fetal 
growth abnormalities are typically progressive. Therefore, capturing the earliest moment when they emerge is essential 
to guide subsequent obstetric management. 
Material and methods: We aimed to analyze fetal ultrasound growth trajectories in type 1 diabetics. Moreover, we aimed 
to establish time points when first ultrasound manifestations of fetal growth abnormalities appear and to identify factors 
that affect fetal growth in women with diabetes.
We collected clinical and ultrasound data from 200 patients with PGDM managed in the third-referential centre for diabetes 
in pregnancy. During every visit, patients underwent an ultrasound examination according to a standard protocol giving 
1072 ultrasound scan’s records. Every ultrasound consisted of fetal weight estimation, according to the Hadlock 3 for-
mula. Retrospectively patients were divided into three groups depending on neonatal weight. In the group of 200 patients, 
60 (30%) delivered LGA and 9 (4.5%) SGA newborns.
Results: Fetal growth trajectories show different patterns among fetuses with growth abnormalities in women with 
type 1 diabetes. The moment, when fetal growth curves diverge, seems to take place in the second trimester, just after  
the 23rd week of gestation.
Conclusions: It suggests that fetal growth abnormalities in type 1 diabetes may have its roots much earlier than expected. 
In the first trimester, there were differences in LDL-cholesterol, total cholesterol, triglyceride levels and in insulin require-
ments between AGA, SGA and LGA subgroups.
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INTRODUCTION 
Pregnancy in diabetic patients increases the risk of de-
veloping maternal and fetal complications. Pregestational 
diabetes mellitus (PGDM) complicates about 0.2–0.3% 
of pregnancies, depending on the studied population [1]. 
Patients with diabetes are much more likely to develop 
obstetric complications such as pregnancy-induced hy-
pertension, preeclampsia and polyhydramnios. Premature 
births, operational deliveries, perinatal infections are also 
much more common in that group of patients [2–4]. Acute 
carbohydrate disturbances may pose a direct threat to the 
life of the pregnant woman and fetus. 
Among fetal complications we can distinguish congeni-
tal malformations, neonatal hypoglycemia and in particular 
excessive growth of the fetus (LGA, large for gestational 
age), which is often the cause of perinatal injuries [5]. 
Depending on the type of diabetes this complication con-
cerns 15% to even 50% of pregnant women with type 
1 diabetes [6].
Fetuses of mothers with pregestational diabetes mel-
litus are particularly vulnerable to complications during 
pregnancy and the percentage of pregnancies complicated 
by excessive growth continues to increase despite improved 
diabetes management [1]. 
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Fetal overgrowth is challenging to predict and capture 
early during pregnancy. It affects mainly children exposed in 
utero to maternal hyperglycemia, followed with fetal hyper-
insulinemia. Moreover, studies are suggesting the involve-
ment of other factors including maternal lipids, adipokines 
and excessive weight gain [7]. These newborns are also at 
risk of obesity, diabetes and cardiovascular disease later in 
life [8, 9]. Most of the fetal complications are irreversible, 
so capturing the earliest moment when growth disorders 
occur to prevent this process is essential.
Due to the still inaccurate ultrasound diagnostics and 
severe consequences for the neonatal health that result 
from undetected fetal overgrowth, special attention should 
be placed on the best obstetric and diagnostics procedures 
for diabetic pregnant women to prevent them.
Our work aimed to assess the incidence of disturbances 
in the fetal growth in the studied group of patients with 
pre-existing type 1 diabetes and to analyze the ultrasound 
growth charts of fetuses from the examined group of preg-
nant women to indicate the period of pregnancy in which 
they begin. The next goal is to identify factors that signifi-
cantly affect fetal growth in pregnant women with diabetes. 
Spotting of this moment and identifying factors influ-
encing the fetal growth disturbances would possibly allow 
identifying a group of women particularly predisposed to 
these complications.
MATERIAL AND METHODS
In line with the Polish standards of medical care each 
woman with pregestational diabetes was admitted to our 
department the tertiary reference centre for pregnant dia-
betic women from central-west Poland, as soon as her pri-
mary care gynaecologist confirmed the pregnancy.
We collected data from 200 pregnancies with pregesta-
tional type 1 diabetes mellitus (PGDM1) that we admitted in 
the first trimester to our department in 2015–2018. Patients 
were regularly admitted in the clinic in every trimester to 
assess health status, metabolic control, and to supervise 
the fetal development. During every visit, each patient un-
derwent an ultrasound examination by an experienced 
sonographer according to a standard protocol. In the study, 
based on biparietal diameter (BPD), head circumference 
(HC), abdominal circumference (AC) and femur length (FL) 
measurements, fetal weight was estimated according to the 
Hadlock 3 formula, which is considered to be the most ac-
curate estimation of fetal weight in diabetic pregnancies [2].
We analyzed data of diabetic, singleton pregnancies 
we retrospectively retrieved from our department’s data-
base. All women conceived naturally. Analyzed patients 
were admitted to our department at least once before the 
12th week of pregnancy, according to the last menstrual 
period (LMP). Gestational age was confirmed or corrected 
in the first trimester of pregnancy with the measurement 
with transvaginal ultrasound. Each pregnant woman with 
type 1 diabetes admitted to the department we thoroughly 
interviewed during the first antenatal visit. Only patients 
admitted in the first trimester were taken into the study.
Patients were all Caucasian and received standard preg-
nancy care for patients with diabetes, as recommended 
by the Polish Diabetes Association and Polish Gynaeco-
logical Society. As target we took a fasting glucose level of 
3.9–5 mmol/L (70–90 mg/dL), 1-hour postprandial glucose 
below 7.8 mmol/L (140 mg/dL), and glycated haemoglobin 
(HbA1c) below 6.5 % (48 mmol/L) in the first trimester of 
pregnancy and next trimesters below 6.0% (42 mmol/L) [4]. 
At the first antenatal visit we recorded the following 
maternal parameters: maternal age, duration and class of 
diabetes according to White, pre-pregnancy body mass 
index (BMI), the concentration of haemoglobin A1c (HbA1c), 
presence of vascular complications (hypertension, protein-
uria, and retinopathy) and pregnancy planning. 
All women were on intensive insulin therapy using either 
multiple daily injections (MDI) or continuous subcutaneous 
insulin infusion (CSII). 
Exclusion criteria from this paper were multiple preg-
nancies, miscarriage, preeclampsia and delivery before com-
pleted the 34th week of gestation or delivery in another 
hospital.
We collected anthropometric, clinical and laboratory 
data during three planned hospital admissions, according 
to our protocol: in the first trimester (< 12th week of gesta-
tion), in mid-pregnancy (20th–24th weeks of pregnancy) and 
before delivery (34th–39th weeks of gestation).
The term large‐for‐gestational‐age we used for fetuses 
or newborns with estimated weight above the 90th percen-
tile or more than two standard deviations from the mean for 
the gestational age. Small for gestational age refers to fe-
tuses or neonates that were born with weight below the 
10th centile or more than two standard deviations from 
the mean for the gestational age adjusted to World Health 
Organization definitions [5].
Blood samples were taken for analysis after overnight, 
in the fasting state and immediately transported to the 
central laboratory of the Gynaecologic Obstetrical Univer-
sity Hospital in Poznan. HbA1c level in the whole blood 
was determined using the turbid metric inhibition immu-
noassay, Tina-quant Haemoglobin A1c II test in a Cobas 
c311 analyzer (Roche Diagnostics, Basel, Switzerland). The 
normal range for this test is 4.8–6.0% (29–42 mmol/mol) for 
a non-pregnant population. The total serum cholesterol, 
high density lipoprotein (HDL)-cholesterol and triglycer-
ide (TG) levels were determined with Roche Diagnostics 
reagents (Cholesterol CHODPAP, HDL-C plus and Triglyc-
erides GPO-PAP, respectively) on a Cobas c501 analyzer. 
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The following formula we used to calculate the level of 
low-density lipoprotein (LDL) [LDL-cholesterol = total cho-
lesterol – HDL-cholesterol – (TG/5)]. Total cholesterol (CHOL), 
LDL-cholesterol (LDL-CH), HDL-cholesterol (HDL-CH), and 
triglycerides (TG) levels were measured with the appropriate 
Roche Diagnostics reagents (cholesterol CHOD-PAP, HDL-C 
plus and triglycerides GPO-PAPrespectively) on Hitachi 
912 analyzer. Reference values for CHOLis 3.9–7.2 mmol/L, 
TG is 0.46–1.71 mmol/L, for LDL-CH is 4.1 mmol/L and for 
HDL-CH < 1.29 mmol/L for women.
We performed statistical analysis using PQstat program. 
The Shapiro-Wilik test we used for testing the normality of 
data distribution. We used the ANOVA test to check the 
significance of the difference between three groups, if data 
fitted normal distribution. Results are as the mean ± stan-
dard deviation (SD). Comparisons of non-normally distrib-
uted data are using the Kruskal-Walis test with conclusions 
expressed as the median and interquartile range (IQR). Pa-
rameters that shown significant differences in ANOVA and 
Kruskal-Walis tests were further analyzed with post-hoc 
analysis with approppriately Fisher LSD and Dunn Bonfer-
roni tests to find the differences between the subgroups. 
RESULTS
In our 200 of PGDM1 group, sixty (30%) patients gave 
birth to children meeting LGA criteria, and nine (4.5%) new-
borns were small for gestational age. The birth weight of the 
remaining newborns (n = 131, 65.5%) was appropriate for 
the gestational age (AGA). Maternal parameters related to 
the bodyweight of the newborn divided into three groups 
(LGA, AGA, and SGA), are presented in the Table 1.
The Figure 1 shows fetal growth charts in these three 
subgroups of patients (AGA, SGA, LGA). We present sub-
sequent ultrasound examinations on a scatter plot with 
a superimposed trend line, which maps the trajectory of 
fetal growth in selected groups.
Data has shown that both estimated fetal weight and 
abdominal circumference start to differ between our three 






n = 9 p*
Diabetes duration [years] (SD) 10.8 (7.7) 11.2 (7.5) 9.2 (6.1) 1
Mean age of DM diagnosis [years] (SD) 19.3 (9.1) 17.2 (8.5) 18.5 (8.7) 0.9
Body weight before pregnancy [kg] (SD) 73.1 (18.2) 70 (17.4) 90.2 (14.4) 0.09
Weight gain during pregnancy [kg] (SD) 11.9 (5.7)1 14.7 (4.7)1 11.7 (4.9) 0.5
Weight gain in 1st trimester [kg] (SD) 1.1 (2.2) 0.8 (3.1) 1.4 (1.8) 0.4
Weight gain in 2nd trimester [kg] (SD) 4.7 (3.7) 5.7 (3.8) 3.4 (3.1) 0.7
Weight gain in 3rd trimester [kg] (SD) 5.5 (4.3) 7.0 (5.1) 5.3 (2.6) 0.7
*Kruskal-Walis and ANOVA tests comparing three study groups; 1comparing two groups AGA vs LGA with Mann-Whitney test (p< 0.05); SD — standard deviation;  
SGA — small for gestational age; AGA— appropiate for gestational age; GA— gestational age
Figure 1. Estimated fetal weight in ultrasound according to the final weight of the newborns — three groups: SGA (yellow), AGA (green), LGA 
(blue) SGA — small for gestational age; AGA — appropiate for gestational age; LGA — large for gestational age
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groups around the 23rd week (161 days). Similar results were 
presented by other authors [10]. Abdominal circumference is 
a measurement that varies the most the fetuses with growth 
disorders, as well as with excessive as with too small fetal 
growth. In our diabetic group we observed differences in 
abdominal circumference, especially in the LGA fetuses 
in the third trimester (Fig. 2).
In the next part of our study we analyzed the metabolic 
parameters of the patients to show which of them had 
a significant impact on the development of excessive fetal 
growth. Our results have shown, that there was no difference 
in any of the studied parameters between patients who 
delivered LGA and AGA newborns and all of them met the 
target criteria of glycemic control. The percentage of HbA1c, 
which reflects the mean glycemia was not significantly dif-
ferent between the LGA and AGA group. SGA patients had 
higher HbA1c levels in the first trimester, but this difference 
was not significant (Tab. 2). In none of the trimesters HbA1c 
concentrations were statistically different between LGA, 
SGA, and AGA patients. 
Also the concentration of the maternal lipids concen-
trations (HD-L, LDL-, total cholesterol and triglycerides) 
analyzed in each of the three trimesters did not differ sig-
nificantly between diabetic patients with excessive and 
with proper fetal growth. We found somewhat surprising 
differences between the SGA and the AGA groups. SGA 
patients had a substantially higher level of the total choles-
terol, LDL-cholesterol and triglycerides in the first trimester 
(p < 0.05). They also needed more insulin in the first and 
second trimester to maintain euglycemia (p = 0.05). Interest-
ing differences we found in weight gain during pregnancy 
(p < 0.05) Women who delivered LGA neonates presented 
higher weight gain during pregnancy than AGA group.
For the analysis of the effectiveness of fetal weight pre-
diction before delivery we qualified 87 patients whose ul-
trasound was performed up to seven days before childbirth. 
We predicted in 69 (79%) a weight as being appropriate for 
gestational age. After birth this diagnosis was confirmed in 
59 (68%) newborns. Eight newborns (9%) turned out to be 
LGA, while two belonged to the SGA group. Predicting LGA 
based on EFW was less sensitive than based on abdominal 
circumference. Our results revealed that AC measurements 
had higher accuracy in LGA detecting and lower negative 
predictive value, which is crucial to avoid perinatal injuries 
in diabetic pregnancies (Tab. 4, 5)
DISCUSSION
Pregestational diabetes may lead to many maternal 
complications during pregnancy but especially coincides 
with the development of adverse neonatal outcomes. One 
of the most common complications is excessive fetal growth, 
which can be associated with fetal fetopathy including met-
abolic disturbances and the risk of shoulder dystocia [4]. 
There is no one specific formula for fetal weight estima-
tion in small for gestational age fetuses as well as in big 
babies. Coombs et al. [11] compared 31 formulas in their 
study and did not show significant superiority of individual 
methods. Many authors have proved that Hadlock’s formula 
is the best for estimating the weight of hypotrophic fetuses, 
as well as the macrosomic babies. Therefore we decided to 
use it for our measurements [12]. 
Excessive fetal growth increases the risk of cesarean sec-
tion and traumatic delivery [5]. To predict and avoid these 
complications precise estimating of fetal weight in ul-
trasound is necessary. Also very important is to find the 
moment when fetal overgrowth is starting, because then 
Figure 2. Abdominal circumference (AC) in ultrasound according to the final weight of the newborns — three groups: SGA (yellow), AGA (green), 
LGA (blue) SGA — small for gestational age; AGA — appropiate for gestational age; LGA — large for gestational age
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we have the possible chance to intensify the metabolic 
and maternal weight gain control. 
In our study we tried to determine the week of preg-
nancy when excessive fetal weight gain begins. In daily clini-
cal practise we observe that children who are macrosomic 
after delivery, start their excessive weight gain around the 
26th–28th weeks of pregnancy. Determining the growth tra-
jectories for fetuses with AGA, LGA and SGA in our studied 
groups we noticed the tendency to diverge curves distinctly 
earlier, i.e. from 24–25 weeks of pregnancy. In our study, 
we estimated the moment when fetal growth impairment 
begins among patients with pregestational diabetes. How-
ever statistical analyzes have not confirmed this. They have 
shown that based on the available data we are not able to 
determine the exact moment when the excessive growth 
of the fetus or its restriction begins. We speculate that our 
studied group, however well treated with proper metabolic 
control is quite heterogeneous and it might impair the preci-
sion of this finding. Patients differ in duration of the disease, 
weight gain during pregnancy, total insulin doses, presence 
of vascular and renal complications and this complexity of 
the diabetic disease potentially causes a different moment 
of the beginning of fetal growth disturbances. 
The proper on time detection of this process might give 
in impulse for better glycemic and weight gain control, 
which in some studies confirmed the suppressing of fetal 
overgrowth [13]. Our observations might constitute a moti-
vation for searching for better indicators of growth impair-
ment in the early stages of pregnancy. From all measured 
metabolic parameters in our studied group only maternal 
weight gain during pregnancy differed significantly the 
groups with LGA and AGA newborns. It shows that higher 
energy intake determines not only maternal weight gain 
but also affects fetal weight. In the SGA group patients were 
heavier at the beginning of pregnancy, had significantly 
higher triglycerides in I and II trimester and insulin intake 
during the second trimester. Surprisingly only two patients 
from that group presented hypertension during pregnancy. 






n = 9 p*
HbA1c 1st trimester [%] (SD) 6.9 (1.6) 6.5 (1.1) 7.1 (1.8) 0.2
HbA1c 2nd trimester [%] (SD) 5.7 (0.7) 6.8 (8.1) 5.3 (0.8) 0.5
HbA1c 3rd trimester [%] (SD) 6.0 (0.7) 5.9 (0.8) 6.1 (1.4) 0.9
HDL 1st trimester [mg/dL] (SD) 68.6 (17.1) 70.3 (17.5) 60.7 (22.3) 0.5
HDL 2nd trimester [mg/dL] (SD) 85.1 (19.0) 89.0 (19.6) 73.9 (9.6) 0.2
HDL 3rd trimester [mg/dL] (SD) 76.8 (19.2) 79.4 (20.3) 71.4 (22.1) 0.7
LDL 1st trimester [mg/dL] (SD) 85.3 (24.1)1 79.1 (20.6)6 100.5 (35.4)1.6 0.01
LDL 2nd trimester [mg/dL] (SD) 127.4 (96.8) 120.1 (35.1) 124.4 (34.6) 0.9
LDL 3rd trimester [mg/dL] (SD) 146.5 (54.0) 140.7 (42.3) 148.6 (29.6) 0.8
Total cholesterol 1st trimester [mg/dL] (SD) 170.1 (27.4)2 163.3 (25.1)7 186.7 (39.8)2.7 0.01
Total cholesterol 2nd trimester [mg/dL] (SD) 230.1 (41.2) 233.7 (51.2) 248.4 (39.4) 0.7
Total cholesterol 3rd trimester [mg/dL] (SD) 269.3 (67.5) 296.0 (231.1) 260.5 (46.6) 0.9
TG 1st trimester [mg/dL] (SD) 83.1 (44.4) 69.8 (29.5)5 127.6 (68.0)5 0.01
TG 2nd trimester [mg/dL] (SD) 148.5 (70.0) 142.3 (52.3) 194.1 (56.8) 0.3
TG 3rd trimester [mg/dL] (SD) 248.8 (89.6) 219.4 (93.2) 258.9 (86.9) 0.2
Hypertensionn (%) 25 (19.2) 10 (16.7) 2 (22.2) 0.7
Proteinuria 1st trimester n (%) 13 (12.3) 8 (17.4) 0 0.4
Proteinuria 2nd trimester n (%) 12 (18.1) 3 (10.7) 0 0.4
Presence of proteinuria 3rd trimester n (%) 15 (6.6) 8 (38.1) 1 (20) 0.9
Insulin intake 1st trimester [IU] (SD) 38.0 (17.4)3 30.0 (17.4)3.8 48.6 (25.7)8 0.01
Insulin intake 2nd trimester [IU] (SD) 42.0 (18.5)4.9 37.1 (19.5) 68.0 (33.7)4.9 0.01
Insulin intake 3rd trimester [IU] (SD) 34.3 (18.1) 30.4 (15.1) 38.8 (23.5) 0.4
Insulin intake per kg
I trimester [IU/kg] (SD) 0.49 (0.28) 0.53 (0.22) 0.51 (0.35) 0.5
*Kruskal-Walis and ANOVA tests comparing three study groups; 1, 2, 3, 4, 6, 7, 8, 9 POST-HOC statistically significant difference p < 0.05. Fisher LSD test; 5POST-HOC statistically 
significant difference p < 0.05. Dunn Bonferroni test; SD — standard deviation; SGA — small for gestational age; AGA — appropiate for gestational age; GA — gestational 
age; HDL — high density lipoprotein; LDL — low-density lipoprotein; TG — triglyceride
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70 (3.5) 72.2 (2.7) 53.5 (35.7) 0.1
*- Kruskal-Walis and ANOVA tests comparing three study groups 
1,3,4,6,7,8- POST- HOC statistically significant difference p<0,05. Fisher LSD test. 
2,5- POST- HOC statistically significant difference p<0,05. Dunn Bonferroni test. 
SD — standard deviation; SGA — small for gestational age; AGA — appropiate for gestational age; GA — gestational age; BPD — biparietal diameter; HC — gead 
circumference; AC — abdominal circumference; FL — femur lenght
Table 4. Prediction of the occurrence of large for gestational age based on EFW
born LGA born AGA sum
predicted LGA 12 1 13
predicted AGA 8 59 67
sum 20 60 80
sensitivity 60.00%
specifity 98.33%
Positive predictive value 92.31%
Negative predictive value 88%
LGA — large for gestational age; AGA — appropiate for gestational age
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Table 5. Prediction of the occurrence of large for gestational age based on AC
born LGA born AGA sum
predicted AC ≥ 90 percentile 16 3 19
predicted AC < 90 percentile 4 57 61
sum 20 60 80
sensitivity 80.00%
specifity 95.00%
Positive predictive value 84.00%
Negative predictive value 93.00%
LGA — large for gestational age; AGA — appropiate for gestational age; AC — abdominal circumference
Still, as we know parameters mentioned above belong to the 
group of metabolites that predispose to changes in placen-
tal vessels and could cause insufficient placental circulation 
resulting in growth restriction.
Our results confirmed that in women with suspicion of 
LGA we may estimate it more precisely, using abdominal 
circumference calculation, than using the estimated fetal 
weight. Abdominal circumference above the 90th-centile has 
higher negative predictive value in detecting LGA than 
the estimation of fetal weight, which allows the obstetri-
cian to plan the route of delivery with higher accuracy. Our 
results are not in concordance with Blue, who observed 
that after the 24th week of gestation AC measurement has 
no advantage in the LGA risk assessment in fetuses with 
estimated overgrowth [14]. Caradeux has not confirmed the 
effectiveness of longitudinal growth assessment as a better 
method to detect excessive growth compared to standard 
biometric measurements [15]. In our opinion although fetal 
weight estimation is still imperfect there is no better way, as 
longitudinal observations to diagnose hypertrophy among 
fetuses. It is in line with Ben-Haroush [16].
Accurate estimation of fetal weight is fundamental both 
to predict the occurrence of complications and also involves 
the choice of delivery method. In the study of Phillips et al. 
the effectiveness of ultrasound performed two weeks before 
delivery in predicting macrosomia was only 33% [17]. Their 
study shows how unpredictable can be the weight of the 
fetus and how dynamically it changes, especially in the last 
weeks of pregnancy, in which we decide about the method 
of delivery. Ben-Haroush in his review concludes that based 
on the available methods we are not able to determine the 
birth weight of fetuses accurately in women with diabetes 
[16]. His observation makes the choice of delivery more 
challenging and therefore increasing the risk of shoulder 
dystocia. In our study we estimated the risk of macrosomia 
using known risk factors. We took into consideration prior 
history of macrosomia, maternal pre-pregnancy weight, 
weight gain during pregnancy, multiparity, fetal sex (male), 
gestational age (40 weeks), maternal birth weight, and ma-
ternal height and obesity [17]. We confirmed that the total 
maternal weight gain in a relatively well-controlled diabetic 
group predisposes significantly to fetal overgrowth.
The main goal of our study was to indicate the moment 
when growth disorders begin to develop. Schaefer-Graf 
et al. revealed that the following factors were leading in 
the late second and early third trimesters, genetic and pa-
tient’s history turned out to be the most significant factors 
influencing fetal growth. In the late third-trimester maternal 
hyperglycemia has the most significant influence on the 
macrosomia [18]. In our group of patients the maternal 
weight gain throughout pregnancy was the only statistically 
significant factor that correlated with macrosomia.
We assume that it is the matter of vital importance not to 
stop looking for new parameters to diagnose both excessive 
growth and growth restriction as soon as possible during 
pregnancy. Especially in the group of patients with the 
disease predisposing to these complications like with pre-
gestational diabetes. Our results confirmed that in patients 
with an efficient metabolic control the next steps should be 
done. Strict weight gain control during pregnancy, planning 
the pregnancy by reducing the body weight and treatment 
of hypertriglyceridemia before pregnancy might let to avoid 
impaired fetal growth. Maybe further studies will find some 
vascular complications in early pregnancy, putting such 
patients to a group of the high risk of developing growth 
restriction.
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